Gene
BTBD7
BTBD7 is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (5), Target-disease associations (30), and 3 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
6 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the papers our biomarker dictionary matched in a year mention BTBD7. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
BTBD7 has 5 publication mentions across 5 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Publication mentions | Share of that year |
|---|---|---|
| 2023 | 1 of 11,460 | 0.01% |
| 2022 | 0 of 13,598 | 0.00% |
| 2021 | 1 of 15,045 | 0.01% |
| 2020 | 1 of 14,459 | 0.01% |
| 2019 | 0 of 12,159 | 0.00% |
| 2018 | 0 of 11,854 | 0.00% |
| 2017 | 0 of 11,595 | 0.00% |
| 2016 | 0 of 10,983 | 0.00% |
| 2015 | 0 of 11,395 | 0.00% |
| 2014 | 1 of 10,367 | 0.01% |
Showing 10 of 34 years.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| Idylla CDx MSI Test | BTBD7 | Biocartis US, Inc. | Colorectal Cancer (CRC) | 2025-08-15 |
Assay-provider ledger (5)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Biocartis | Diagnostic provider | Clinical validation | 3 | September 01, 2025 |
| Agilent Technologies | Reagent supplier | Clinical validation | 1 | July 24, 2021 |
| DAKO (Carpinteria, CA, USA) - IHC antibodies and Autostainer Link 48 platform | Context dependent | Clinical validation | 1 | July 24, 2021 |
| Diatech Pharmacogenetics | Diagnostic provider | Clinical validation | 1 | July 24, 2021 |
| Qiagen (Hilden, Germany) - Mini Amp DNA extraction kit | Reagent supplier | Clinical validation | 1 | July 24, 2021 |
Target-disease associations (30)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Hearing loss - familial salivary gland insensitivity to aldosterone | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Salivary Gland Pleomorphic Adenoma | gastrointestinal disease | Mouse knockout (IMPC) |
| adrenal cortex carcinoma | cancer or benign tumor | Literature (Europe PMC) |
| arterial stiffness measurement | measurement | GWAS credible sets |
| body mass index | measurement | GWAS credible sets |
Showing 5 of 30 associations.
Vendor sourcing (2)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.2771G>A (p.R924Q) alteration is located in exon 11 (coding exon 10) of the BTBD7 gene. This alteration results from a G to A substitution at nucleotide... | View ClinVar record SCV003543093.3 |
| Not resolved to an organization | Diagnostics manufacturer | FDA-authorized companion diagnosticFDA companion diagnostic authorization | Microsatellite instability-High (MSI-H) | View FDA device record |
Trial-cited literature (5)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Web-Based Asynchronous Tool to Facilitate Communication Between Primary Care Providers and Cancer Specialists: Pragmatic Randomized Controlled Trial. | Journal of medical Internet research | 2023 | 7 |
| Tracking tDCS induced grey matter changes in episodic migraine: a randomized controlled trial. | The journal of headache and pain | 2021 | 8 |
| Automatic mandibular canal detection using a deep convolutional neural network. | Scientific reports | 2020 | 85 |
| Three-dimensional organotypic culture: experimental models of mammalian biology and disease. | Nature reviews. Molecular cell biology | 2014 | 549 |
| Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. | The British journal of dermatology | 2013 | 79 |
Organizations publishing (7)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Johns Hopkins University | Academic | 1 | 2014 |
| McMaster University | Academic | 1 | 2023 |
| Pusan National University | Academic | 1 | 2020 |
| Seoul National University | Academic | 1 | 2020 |
| University Hospital Zurich | Hospital | 1 | 2021 |
Showing 5 of 7 organizations.
Where BTBD7 appears
- cancer or benign tumor
- cardiovascular disease
- gastrointestinal disease
- genetic, familial or congenital disease
- measurement
- nutritional or metabolic disease
- phenotype
30 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects, actionable biomarkers, trial mentions, protein variant mentions, human sample screening reference, and literature-extracted relations.